NORD Issues Statement on FDA’s New Associate Director for Rare Diseases
Written by Jennifer Huron on July 23, 2015
The following statement was issued by Peter L. Saltonstall, President and CEO of the National Organization for Rare Disorders (NORD), on today’s announcement that Jonathan C. Goldsmith, MD, FACP, will lead the Rare Diseases Program in the Center for Drug Evaluation and Research (CDER) Office of New Drugs at the… Read More